Arrowhead Pharmaceuticals (ARWR) Reports Q4 Loss of $1.34
Tweet
Share
E-mailGet Alerts ARWR Hot Sheet
Price: $88.51 +2.16%
Financial Fact:
OPERATING LOSS: -19.34M
Today's EPS Names:
MSGM, SMID, VISL, More
Financial Fact:
OPERATING LOSS: -19.34M
Today's EPS Names:
MSGM, SMID, VISL, More
Join SI Premium – FREE
Arrowhead Pharmaceuticals (NASDAQ: ARWR) reported Q4 EPS of ($1.34), versus ($1.60) reported last year. Revenue for the quarter came in at $158.33 thousand versus the consensus estimate of $382 thousand.
For earnings history and earnings-related data on Arrowhead Pharmaceuticals (ARWR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Smith-Midland Corporation (SMID) Tops Q2 EPS by 26c
- Jasper Therapeutics (JSPR) Tops Q2 EPS by 18c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
